JP7277390B2 - 抗癌／抗線維症化合物 - Google Patents

抗癌／抗線維症化合物 Download PDF

Info

Publication number
JP7277390B2
JP7277390B2 JP2019572809A JP2019572809A JP7277390B2 JP 7277390 B2 JP7277390 B2 JP 7277390B2 JP 2019572809 A JP2019572809 A JP 2019572809A JP 2019572809 A JP2019572809 A JP 2019572809A JP 7277390 B2 JP7277390 B2 JP 7277390B2
Authority
JP
Japan
Prior art keywords
compound
salt
substituted
hydrate
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019572809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529396A5 (enExample
JP2020529396A (ja
Inventor
エム． ジャブロンズ，デイビッド
シュウ，ウェイ
ヨウ，リャン
リウ，シュウ
ユアン，シェンドン
マ，サンフン
マック，モリソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020529396A publication Critical patent/JP2020529396A/ja
Publication of JP2020529396A5 publication Critical patent/JP2020529396A5/ja
Application granted granted Critical
Publication of JP7277390B2 publication Critical patent/JP7277390B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019572809A 2017-07-31 2018-07-31 抗癌／抗線維症化合物 Active JP7277390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539237P 2017-07-31 2017-07-31
US62/539,237 2017-07-31
PCT/US2018/044663 WO2019028059A1 (en) 2017-07-31 2018-07-31 ANTICANCER COMPOUNDS / ANTI-FIBROSIS

Publications (3)

Publication Number Publication Date
JP2020529396A JP2020529396A (ja) 2020-10-08
JP2020529396A5 JP2020529396A5 (enExample) 2021-09-09
JP7277390B2 true JP7277390B2 (ja) 2023-05-18

Family

ID=65233035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572809A Active JP7277390B2 (ja) 2017-07-31 2018-07-31 抗癌／抗線維症化合物

Country Status (6)

Country Link
US (1) US11932606B2 (enExample)
EP (1) EP3661512A4 (enExample)
JP (1) JP7277390B2 (enExample)
CN (1) CN111447931B (enExample)
CA (1) CA3067871A1 (enExample)
WO (1) WO2019028059A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028059A1 (en) * 2017-07-31 2019-02-07 The Regents Of The University Of California ANTICANCER COMPOUNDS / ANTI-FIBROSIS
EP4003339A4 (en) * 2019-07-30 2023-02-22 Sanford Burnham Prebys Medical Discovery Institute DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093465A1 (en) 2007-08-31 2009-04-09 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
JP2010502651A (ja) 2006-09-01 2010-01-28 サイリーン ファーマシューティカルズ インコーポレーティッド セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
JP2012524076A (ja) 2009-04-17 2012-10-11 サイリーン ファーマシューティカルズ インコーポレーティッド プロテインキナーゼｃｋ２活性に関連する障害の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648021A (en) * 1994-01-17 1997-07-15 Hoechst Aktiengesellschaft Phenanthrene derivatives and their use in liquid-crystalline mixtures
DE19524230A1 (de) * 1995-07-04 1997-01-09 Hoechst Ag Fluorierte Phenanthren-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
KR19990029052A (ko) * 1995-07-17 1999-04-15 악커만 요아힘, 되르 클라우스 강유전성 액정 혼합물
EP1904449A4 (en) * 2005-07-08 2010-07-28 Merck Sharp & Dohme CHECKPOINT KINASE INHIBITORS
BR112012005970A2 (pt) * 2009-09-16 2015-09-08 Cylene Pharmaceuticals Inc moduladores tricíclicos de proteína quinase
US10432142B2 (en) * 2017-07-21 2019-10-01 Oracle International Corporation Voltage controlled oscillator with tunable inductor and capacitor
WO2019028059A1 (en) * 2017-07-31 2019-02-07 The Regents Of The University Of California ANTICANCER COMPOUNDS / ANTI-FIBROSIS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502651A (ja) 2006-09-01 2010-01-28 サイリーン ファーマシューティカルズ インコーポレーティッド セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
US20090093465A1 (en) 2007-08-31 2009-04-09 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
JP2012524076A (ja) 2009-04-17 2012-10-11 サイリーン ファーマシューティカルズ インコーポレーティッド プロテインキナーゼｃｋ２活性に関連する障害の治療方法

Also Published As

Publication number Publication date
EP3661512A1 (en) 2020-06-10
JP2020529396A (ja) 2020-10-08
WO2019028059A1 (en) 2019-02-07
US20230192621A1 (en) 2023-06-22
CN111447931A (zh) 2020-07-24
US11932606B2 (en) 2024-03-19
CN111447931B (zh) 2024-01-26
EP3661512A4 (en) 2020-12-30
CA3067871A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
ES2617905T3 (es) Inhibidores de desmetilasas de histonas
JP7389504B2 (ja) がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物
ES2930305T3 (es) Inhibidores del bromodominio
ES2917979T3 (es) Derivados de Piridazina 1,4-disustituidos y su uso para tratar afecciones relacionadas con la deficiencia de SMN
IL293962A (en) Mutant kras protein inhibitors
JP7511557B2 (ja) ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途
ES2929424T3 (es) Compuestos de piridinamina-piridona y pirimidinamina-piridona
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
CN109689652B (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
BR112018075736B1 (pt) Composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
JP2022037004A (ja) 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体
AU2023227010A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
JP2025500917A (ja) Ｍｅｔキナーゼの阻害剤
JP7277390B2 (ja) 抗癌／抗線維症化合物
JP7152078B2 (ja) ホウ酸塩ベースの薬物およびその使用
CN112739695B (zh) 新型噻唑衍生物及其药学上可接受的盐
US20210070779A1 (en) Boron-containing small molecules as anti-inflammatory agents
KR20210151849A (ko) 퀴놀린 유도체 및 암의 치료를 위한 그의 용도
WO2025072673A1 (en) Thiazole derivatives and their use as ire 1 inhibitors
CN120309612A (zh) 一类含二取代7-氮杂吲哚结构的化合物及应用
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途
EA049024B1 (ru) Ингибиторы parp1 на основе азетидина и пирролидина и их применение
TW202312995A (zh) 氮雜芳基化合物、其製備方法及應用
JP2021515045A (ja) インドリジン系化合物、その製造方法及び用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230508

R150 Certificate of patent or registration of utility model

Ref document number: 7277390

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150